相似文献
1
Lack of evidence for a genetic association between FGF20 and Parkinson's disease in Finnish and Greek patients.
BMC Neurol. 2005 Jun 20;5:11. doi: 10.1186/1471-2377-5-11.
2
Fibroblast growth factor 20 gene and Parkinson's disease in the Japanese population.
Neuroreport. 2007 Jun 11;18(9):937-40. doi: 10.1097/WNR.0b013e328133265b.
3
Paraoxonase 1 (PON1) gene polymorphisms and Parkinson's disease in a Finnish population.
Neurosci Lett. 2004 Sep 2;367(2):168-70. doi: 10.1016/j.neulet.2004.05.108.
4
Gene-gene interaction between FGF20 and MAOB in Parkinson disease.
Ann Hum Genet. 2008 Mar;72(Pt 2):157-62. doi: 10.1111/j.1469-1809.2007.00418.x. Epub 2008 Jan 20.
5
Identification of a risk haplotype of the alpha-synuclein gene in Japanese with sporadic Parkinson's disease.
Mov Disord. 2006 Dec;21(12):2157-64. doi: 10.1002/mds.21142.
6
Multiple candidate gene analysis identifies alpha-synuclein as a susceptibility gene for sporadic Parkinson's disease.
Hum Mol Genet. 2006 Apr 1;15(7):1151-8. doi: 10.1093/hmg/ddl030. Epub 2006 Feb 24.
7
Association of a variation in the promoter region of the brain-derived neurotrophic factor gene with familial Parkinson's disease.
Parkinsonism Relat Disord. 2004 Jun;10(4):213-9. doi: 10.1016/j.parkreldis.2003.12.003.
8
The human prion gene M129V polymorphism is not associated with idiopathic Parkinson's disease in three distinct populations.
Neurosci Lett. 2006 Mar 13;395(3):227-9. doi: 10.1016/j.neulet.2005.10.081. Epub 2005 Nov 18.
9
Multiple alpha-synuclein gene polymorphisms are associated with Parkinson's disease in a Norwegian population.
Acta Neurol Scand. 2008 Nov;118(5):320-7. doi: 10.1111/j.1600-0404.2008.01019.x. Epub 2008 May 15.
10
Microtubule-associated protein tau (MAPT) influences the risk of Parkinson's disease among Indians.
Neurosci Lett. 2009 Aug 21;460(1):16-20. doi: 10.1016/j.neulet.2009.05.031. Epub 2009 May 18.
引用本文的文献
1
Quantitative assessment of the effect of FGF20 rs1721100 and rs12720208 variant on the risk of sporadic Parkinson's disease: a meta-analysis.
Neurol Sci. 2022 May;43(5):3145-3152. doi: 10.1007/s10072-021-05754-6. Epub 2021 Nov 29.
2
Circulating proteins protect against renal decline and progression to end-stage renal disease in patients with diabetes.
Sci Transl Med. 2021 Jun 30;13(600). doi: 10.1126/scitranslmed.abd2699.
3
Mechanisms by which fibroblast growth factor 20 improves motor performance in a mouse model of Parkinson's disease.
Neural Regen Res. 2019 Aug;14(8):1438-1444. doi: 10.4103/1673-5374.253527.
4
Genetic analysis of FGF20 in Chinese patients with Parkinson's disease.
Neurol Sci. 2017 May;38(5):887-891. doi: 10.1007/s10072-017-2868-y. Epub 2017 Feb 25.
5
Association between FGF20 rs12720208 gene polymorphism and Parkinson's disease: a meta-analysis.
Neurol Sci. 2016 Jul;37(7):1119-26. doi: 10.1007/s10072-016-2559-0. Epub 2016 Mar 29.
6
Quantitative assessment of the association between fibroblast growth factor 20 rs1721100 C/G polymorphism and the risk of sporadic Parkinson's diseases: a meta-analysis.
Neurol Sci. 2015 Jan;36(1):47-51. doi: 10.1007/s10072-014-1884-4. Epub 2014 Jul 17.
7
Fibroblast growth factor 20 (FGF20) gene polymorphism and risk of Parkinson's disease: a meta-analysis.
Neurol Sci. 2014 Dec;35(12):1889-94. doi: 10.1007/s10072-014-1853-y. Epub 2014 Jun 19.
8
The best-laid plans go oft awry: synaptogenic growth factor signaling in neuropsychiatric disease.
Front Synaptic Neurosci. 2014 Mar 18;6:4. doi: 10.3389/fnsyn.2014.00004. eCollection 2014.
9
Roles of FGF20 in dopaminergic neurons and Parkinson's disease.
Front Mol Neurosci. 2013 May 31;6:15. doi: 10.3389/fnmol.2013.00015. eCollection 2013.
10
Parkinson's disease.
Subcell Biochem. 2012;65:389-455. doi: 10.1007/978-94-007-5416-4_16.
本文引用的文献
1
Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease.
Neuron. 2004 Nov 18;44(4):595-600. doi: 10.1016/j.neuron.2004.10.023.
2
Fibroblast growth factor 20 polymorphisms and haplotypes strongly influence risk of Parkinson disease.
Am J Hum Genet. 2004 Jun;74(6):1121-7. doi: 10.1086/421052. Epub 2004 Apr 30.
3
Genes and parkinsonism.
Lancet Neurol. 2003 Apr;2(4):221-8. doi: 10.1016/s1474-4422(03)00350-8.
4
Preferential neurotrophic activity of fibroblast growth factor-20 for dopaminergic neurons through fibroblast growth factor receptor-1c.
J Neurosci Res. 2003 May 15;72(4):436-43. doi: 10.1002/jnr.10592.
5
Genetics of parkinsonism.
Mov Disord. 2002 Jul;17(4):645-56. doi: 10.1002/mds.10173.
6
Familial aggregation of Parkinson disease: a comparative study of early-onset and late-onset disease.
Arch Neurol. 2002 May;59(5):848-50. doi: 10.1001/archneur.59.5.848.
7
Complete genomic screen in Parkinson disease: evidence for multiple genes.
JAMA. 2001 Nov 14;286(18):2239-44. doi: 10.1001/jama.286.18.2239.
8
Familial aggregation of Parkinson's disease in Iceland.
N Engl J Med. 2000 Dec 14;343(24):1765-70. doi: 10.1056/NEJM200012143432404.
9
FGF-20, a novel neurotrophic factor, preferentially expressed in the substantia nigra pars compacta of rat brain.
Biochem Biophys Res Commun. 2000 Oct 22;277(2):355-60. doi: 10.1006/bbrc.2000.3675.
10
Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease.
J Neurol Neurosurg Psychiatry. 1997 Jan;62(1):10-5. doi: 10.1136/jnnp.62.1.10.
Zotero 插件